A firmer start to 2026

OptiBiotix Health PLC (LSE:OPTI), the York-based life sciences company focused on the human microbiome, has been building momentum through 2026 on the back of larger orders for its weight management ingredient SlimBiome. In January 2026 the company reported more than £800,000 of orders from four partners for delivery during the year, including four large orders from Taiwan's Meelung Trading Co Ltd covering 24 tonnes of SlimBiome, to be delivered roughly every three months. The company described the orders as confirmed with no cancellation clause, and chief executive Stephen O'Hara said they put the business in its best position yet. The shares rose 25% to 8.00p on the day.

What the company does

OptiBiotix develops and commercialises products and ingredients aimed at improving health through the gut microbiome. Its main commercial products include SlimBiome, a weight management ingredient, and the SweetBiotix platform, which focuses on prebiotic fibres. It sells to partners in multiple regions, including Asia, Australia and the US, and also operates an ecommerce channel. The company holds investments in ProBiotix Health and SkinBioTherapeutics.

Latest developments

In a trading update on 1 April 2026 covering the year to 31 December 2025, the company reported revenue of £1.13m, up 30%, and sales orders of £1.34m, up 33%, including £212,000 carried forward for delivery in 2026. Gross profit rose 82% to £603,000, lifting the gross margin to 53% from 38%. Operational highlights included the launch of SlimBiome in Hydroxycut, which the company described as the top-selling weight loss supplement brand in the US, the launch of 17 products for Asian customers, and a new enzyme-based production process for SweetBiotix that offers higher yields and lower costs.

The company also set out a cost reduction programme. Marketing and selling costs fell 78% in January and February 2026, and it expects annual savings of £500,000 to £600,000. SlimBiome production costs were expected to fall 31% on second-quarter 2026 orders.

Financial picture

Operating costs were broadly flat at £2.6m in 2025, excluding share-based payments, while the year-end cash balance was £1.03m, up from £739,000. The holdings in ProBiotix Health and SkinBioTherapeutics were valued at £6.45m combined at the end of 2025, although the company noted that subsequent SkinBioTherapeutics announcements had reduced the value of that stake. OptiBiotix does not pay a dividend. The combination of rising gross margins, lower overheads and a larger order book for 2026 forms the core of management's argument that the business can move towards profitability, although the company has not set out a specific timeline for reaching that goal.

Sector and index context

The functional ingredients and supplements market is competitive and driven by consumer trends in weight management and gut health. Small suppliers depend on winning partner launches and scaling volumes to cover fixed costs. Within the FTSE AIM All Share Index, OptiBiotix is a micro-cap whose progress is measured largely by order flow and its path towards profitability.

Key risks

Revenue is modest relative to costs, so the company remains reliant on order growth and cost savings to reach breakeven. A handful of larger customers account for a meaningful share of orders, and the value of its investment holdings can fluctuate. Funding needs could arise if growth is slower than planned.

What to watch next

Investors will look for the half-year report for the six months to 30 June 2026, delivery of the scheduled Meelung shipments, further partner launches in the US and Asia, and evidence that lower production costs are lifting margins as planned.